EXICURE, INC.
XCUR evidence brief
What we can confirm
- Market Cap:
- $9.2M
What it means
What to watch
Prepared research question
What matters most for XCUR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XCUR
Exicure, Inc. (XCUR) is a clinical-stage biotechnology company that, after acquiring GPCR USA in January 2025, shifted its focus to developing burixafor (GPC-100) for hematologic diseases, with a completed Phase 2 trial in multiple myeloma and ongoing evaluation of strategic alternatives.
Key risk: No revenue and thin equity
Market Cap
$9.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Exicure, Inc. (XCUR) is a clinical-stage biotechnology company that, after acquiring GPCR USA in January 2025, shifted its focus to developing burixafor (GPC-100) for hematologic diseases, with a completed Phase 2 trial in multiple myeloma and ongoing evaluation of strategic alternatives.
- Exicure acquired GPCR USA in January 2025 and now focuses on the GPC-100 program for stem cell mobilization in hematologic diseases [sec_mda · as of 2026-08-14].
- GPCR USA completed a Phase 2 clinical trial in January 2026 for blood cancer patients eligible for hematopoietic stem cell transplantation [sec_mda · as of 2026-08-14].
- Positive topline Phase 2 data for burixafor (GPC-100) in multiple myeloma were presented at the 2025 ASH Annual Meeting [news · published 2025-12-08].
- As of 2026-06-30, the company reported total revenue of $0.0M, net income of -$1.1M, and shareholders' equity of $1.0M [sec].
- The company is evaluating a range of strategic alternatives including potential acquisitions, financings, and partnerships to maximize stockholder value [sec_mda · as of 2026-08-14].
What works
- Burixafor (GPC-100) has completed a Phase 2 trial with positive topline results in multiple myeloma, demonstrating rapid stem cell mobilization and same-day cell collection [news · published 2025-12-08] [news · published 2026-02-05].
- The company is planning expansion into additional indications such as sickle cell disease and acute myeloid leukemia, broadening the potential utility of GPC-100 [news · published 2025-10-06] [news · published 2025-04-12].
- Exicure has preserved capital and is actively evaluating strategic alternatives, including potential acquisitions and partnerships, to create value [sec_mda · as of 2026-08-14].
What to weigh
- The company has no current product revenue, reporting $0.0M in total revenue as of 2026-06-30 [sec].
- Net income was -$1.1M and shareholders' equity was only $1.0M as of 2026-06-30, indicating a very limited financial runway [sec].
- Exicure is obligated to make milestone payments and recurring royalty payments to GPCR under the License and Collaboration Agreement, which could strain resources [sec_mda · as of 2026-08-14].
- The company's strategic future is uncertain as it evaluates a broad range of alternatives, with no guaranteed path to commercialization or profitability [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Exicure acquired GPCR USA in January 2025 and now focuses on GPC-100.
“Following the acquisition of GPCR USA in January 2025 and changes in our ownership, board composition and management team, our activities have primarily focused on supporting GPCR USA's clinical development programs”
SEC MD&A · August 14, 2026
GPCR USA completed a Phase 2 trial in January 2026 for blood cancer patients.
“GPCR USA completed its Phase 2 clinical trial in January 2026 that focused on blood cancer patients, particularly those eligible for hematopoietic stem cell transplantation”
SEC MD&A · August 14, 2026
Risks & what to watch (3)›
Key risks
- No revenue and thin equity — Total revenue $0.0M, net loss -$1.1M, equity only $1.0M as of 2026-06-30 [sec].
- Milestone payment obligations — Company must make milestone and royalty payments to GPCR, including a $1.0M milestone due Q2 2026 [sec_mda · as of 2026-08-14].
- Strategic uncertainty — Company is evaluating a broad range of strategic alternatives with no guaranteed outcome [sec_mda · as of 2026-08-14].
What to watch
- Completion and results of the ongoing Phase 2 trial combining GPC-100 with propranolol in multiple myeloma patients [sec_mda · as of 2026-08-14].
- Plans for a new clinical trial in acute myeloid leukemia using GPC-100 [news · published 2025-04-12].
- Any announced strategic alternative, such as a potential acquisition, financing, or partnership [sec_mda · as of 2026-08-14].
- Financial runway updates given the low equity and ongoing cash burn [sec].
Sources: News · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run EXICURE, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EXICURE, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$687K
| Holder | Shares | Value |
|---|---|---|
| carlyle group inc. | 56,328 | $240K |
| geode capital management, llc | 36,913 | $158K |
| vanguard capital management llc | 32,983 | $141K |
| vanguard fiduciary trust co | 13,161 | $56K |
| northern trust corp | 10,686 | $45K |
| blackrock, inc. | 9,353 | $40K |
| ubs group ag | 866 | $4K |
| tower research capital llc (trc) | 489 | $2K |
| morgan stanley | 158 | $672 |
| fortitude family office, llc | 120 | $511 |
Showing top 10 of 18 institutional holders of EXICURE, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 1.9%
- Days to cover
- 2.5
- Shares short
- 57,656
- Daily short volume (Oct 12, 2026)
- 20.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XCUR short interestGovernance
Frequently asked questions
What is the AI investment thesis for EXICURE, INC.?
Exicure, Inc. (XCUR) is a clinical-stage biotechnology company that, after acquiring GPCR USA in January 2025, shifted its focus to developing burixafor (GPC-100) for hematologic diseases, with a completed Phase 2 trial in multiple myeloma and ongoing evaluation of strategic alternatives.
Who is the CEO of EXICURE, INC.?
Mr. Jungsoo Kim is the chief executive officer of EXICURE, INC. (XCUR).
Where is EXICURE, INC. headquartered?
EXICURE, INC. (XCUR) is headquartered in Redwood City, CA, United States.
What therapeutic areas does EXICURE, INC. focus on?
EXICURE, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.